/
Lancet Neurol
Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial
- B.A.C. Cree
- H.J. Kim
- B.G. Weinshenker
- S.J. Pittock
- D.M. Wingerchuk
- K. Fujihara
- F. Paul
- G.R. Cutter
- R. Marignier
- A.J. Green
- O. Aktas
- H.P. Hartung
- D. She
- W. Rees
- M. Smith
- D. Cimbora
- E. Katz
- J.L. Bennett